New gel shows promise for vitiligo in Mid-Stage trial
NCT ID NCT06790862
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a gel called SHR0302Base in 155 adults with stable nonsegmental vitiligo. The goal is to see if it can improve skin color on the face and neck by at least 50%. Participants are randomly assigned to get the real gel or a placebo, and neither they nor their doctors know which they receive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR0302Base gel
- What this could lead to
- If successful, this gel could offer a new topical treatment to restore skin color in people with vitiligo, potentially reducing the need for systemic medications.
- What could go wrong
- This is a mid-stage trial with only 155 people, so results may not apply to everyone. The gel may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VITILIGO are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dermatology Hospital affiliated to Shandong First Medical University
Jinan, Shandong, 250022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Real-World data unlock better skin disease care?
- New ointment aims to restore skin color in vitiligo
- Skin microbes linked to vitiligo and immunotherapy reactions in melanoma patients
- New vitiligo registry aims to uncover disease trends in 2,500 patients
- Scientists probe immune secrets of four skin diseases
- Lamp vs laser: which light works best for vitiligo?